- CEO
- Hai Bin Chen
- Full Time Employees
- 7,462
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Building 2 Hangzhou ZH China 310030
- IPO Date
- Jul 19, 2011
- Business
- Dian Diagnostics Group Co., Ltd. Dian Diagnostics Group Co., Ltd. (300244.SZ) operates as a leading provider of integrated medical diagnostics solutions in China, with independent third-party diagnostic services as its core business. The company offers a comprehensive range of products and services, including medical diagnostic services across more than 4,000 parameters; diagnostic technology research and development in genomics, proteinomics, and metabolomics; production and sales of in vitro diagnostic reagents, equipment, laboratory supplies, and kits; molecular diagnosis, pathological diagnosis, and mass spectrometry diagnosis product lines; AI-assisted digital pathology solutions with digital slide scanners and real-time PCR systems; LC-MS/MS and DP-TOF nucleic acid mass spectrometry solutions; forensic drug testing and appraisal services; health management and diagnosis-treatment industrial chain integration; contract research organization (CRO) services; and cold chain logistics, supply chain optimization, and laboratory quality management. Dian Diagnostics Group Co., Ltd. serves over 22,000 medical institutions, including general hospitals, specialty hospitals, community health centers, physical examination centers, and disease control centers, having processed samples for more than 330 million people through its network of over 40 chain medical laboratories, 10 forensic science centers, and 4 health management centers; it operates primarily in China with recent international expansion. Founded in 1996 and headquartered in Hangzhou, Zhejiang Province, China, the company listed on the Shenzhen Stock Exchange in July 2011 and employs over 10,000 people. Recent developments include the establishment of DIAN Laboratory Co., Ltd. in Ho Chi Minh City, Vietnam, in November 2023 to advance global expansion with its "service + product" model; a strategic AI health management cooperation agreement with Huawei Cloud signed in 2024; a letter of intent for cooperation with Gulf Medical University in January 2024; increased investments in AI layout and bad debt reduction through negotiation and litigation announced in 2025; and ongoing collaborations in personalized cancer care and strategic alliances with tech firms for enhanced diagnostic capabilities since 2023.